Clinical Trial Update: A Phase II Clinical Trial to Evaluate HLX208 in Advanced Melanoma Patients With BRAF V600 Mutation [Phase 2]

View source ↗

Summary

Phase II trial evaluating HLX208 in advanced melanoma with BRAF V600 mutation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• HLX208

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: Advanced Melanoma | Phase 2 | Status: UNKNOWN